Table 3 |.

IL-17C in human disease

Mucosal Site	Disease	Main Findings	Reference
Gut	Inflammatory Bowel Disease (IBD)	Increased in UC; correlates with inflammatory activity	[9, 10]
	Helicobacter pylori	Upregulated in gastric mucosa; activates immune response	[12]
	Anti-TNF-α induced psoriaform skin lesion in CD	Elevated in lesions; propagates inflammation	[32]
	Colorectal Cancer (CRC)	Elevated in human CRC	[34]
Skin	Psoriasis	Upregulated in lesions	[13, 28]
	Atopic Dermatitis (AD)	Elevated in keratinocytes and infiltrating immune cells in lesions	[38]
		Inhibition of IL-17C results in downregulation of inflammatory molecules	[39]
Respiratory Tract	Chronic Obstructive Pulmonary Disorder (COPD)	Increased in viral-bacterial coinfection of human bronchial epithelial (HBE) cells	[41]
		Released by Human Rhinovirusinfected HBE cells and contributes to neutrophil recruitment	[42]
	Recurrent Aphthous Ulcers (RAU)	Upregulated in human oral keratinocytes (HOKs) in lesions	[43]
		IL-17C stimulation upregulates TNF-α mRNA production in HOKs	[43]
	Periodontitis	CpG methylation of IL-17C DNA is reduced in aggressive periodontitis	[44]
	Staphylococcal enterotoxin B infection of the nasal passage	Upregulated in response to infection	[45]
	Pseudomonas aeruginosa infection of nasal passage	Controls infection by inhibiting PAO1 siderophore activity	[46]